Evaluation of the predictive and prognostic performance of the PILE score in metastatic renal cell carcinoma
Frontiers in Medicine, cilt.13, 2026 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 13
- Basım Tarihi: 2026
- Doi Numarası: 10.3389/fmed.2026.1835367
- Dergi Adı: Frontiers in Medicine
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, EMBASE, Directory of Open Access Journals, Health Research Premium Collection (ProQuest)
- Anahtar Kelimeler: PILE score, prognostic biomarker, renal cell carcinoma, treatment response, tyrosine-kinase inhibitor
- Açık Arşiv Koleksiyonu: AVESİS Açık Erişim Koleksiyonu
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
The PILE score, integrating pan-immune-inflammation value (PIV), lactate dehydrogenase (LDH), and Eastern Cooperative Oncology Group (ECOG) performance status, has been proposed as a composite biomarker in many cancer types. However, its real-world predictive and prognostic performance remains uncertain in metastatic renal cell carcinoma (mRCC). We retrospectively analyzed 67 patients with mRCC treated with first-line tyrosine kinase inhibitor (TKI) monotherapy at two oncology centers. Patients were stratified into low (0–1) and high (≥2) PILE score groups. Patients with low PILE scores demonstrated significantly higher disease control rates compared with those with high PILE scores (90.0% vs. 58.8%, p = 0.004), along with a numerically higher objective response rate (68.0% vs. 41.2%, p = 0.05), suggesting a potential predictive trend. However, PILE score was not independently associated with progression-free survival (PFS) or overall survival (OS). These findings suggest that the PILE score may function primarily as a predictive marker of treatment response rather than a robust prognostic tool in this setting. Prospective studies are warranted to clarify its potential role in treatment selection.